| Leo Lithium Limited (LLL) ORDINARY FULLY PAID |
Materials |
- |
2024 Corporate Governance Statement
|
27 Feb 2025 6:42PM |
$0.505 |
$0.505 |
fallen by
0%
|
|
| Leo Lithium Limited (LLL) ORDINARY FULLY PAID |
Materials |
- |
Leo Lithium Annual Report 2024
|
27 Feb 2025 6:42PM |
$0.505 |
$0.505 |
fallen by
0%
|
|
| Neurotech International Limited (NTI) ORDINARY FULLY PAID |
Health Care |
$17 |
Appendix 4D and Half Year Accounts
|
27 Feb 2025 6:41PM |
$0.035 |
$0.013 |
fallen by
62.86%
|
|
NTI - Price-sensitive ASX Announcement
Full Release
Key Points
- Neurotech International Limited focuses on paediatric neurological disorders.
- The lead product, NTI164, is a cannabinoid therapy for these disorders.
- For the half-year ending December 31, 2024, the company reported a net loss of $7,447,902.
- There has been significant investment in research and development, totaling $5,690,862.
- The company provided NTI164 to 54 Autism Spectrum Disorder patients during this period.
- Positive results were reported in clinical trials, demonstrating improvements in ASD symptoms.
- Neurotech received an orphan drug designation from the FDA for NTI164 in Rett Syndrome.
- The company completed 20 weeks of treatment in a clinical trial for Rett Syndrome with positive safety results.
- Cash and cash equivalents at December 31, 2024, were reported at $5,948,610.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Spheria Emerging Companies Limited (SEC) ORDINARY FULLY PAID |
Financials |
$146 |
Net Tangible Asset Backing
|
27 Feb 2025 6:31PM |
$2.280 |
$2.430 |
risen by
6.58%
|
|
| Atlas Pearls Ltd (ATP) ORDINARY FULLY PAID |
Consumer Discretionary |
$83 |
Dividend/Distribution - ATP
|
27 Feb 2025 6:29PM |
$0.145 |
$0.190 |
risen by
31.03%
|
|
| Atlas Pearls Ltd (ATP) ORDINARY FULLY PAID |
Consumer Discretionary |
$83 |
Half-Year Financial Report & Dividend Announcement - H1 FY25
|
27 Feb 2025 6:29PM |
$0.145 |
$0.190 |
risen by
31.03%
|
|
ATP - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue from contracts up 29% to $19.1M from H2 FY24
- Net profit after tax of $12.7M for H1 FY25
- Interim and special dividend declared: 1.00 cents/share (unfranked)
- Normalised EBITDA up 21% to $7.1M from H2 FY24
- Average selling price for pearls was $65, down from $103 last year
- Pearls sold increased by 28% to 284,071 in H1 FY25
- Diverse sales channels strengthened, with private sales increasing significantly
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Estrella Resources Limited (ESR) ORDINARY FULLY PAID |
Materials |
$73 |
Cleansing notice under s708A
|
27 Feb 2025 6:28PM |
$0.027 |
$0.033 |
risen by
22.22%
|
|
| Canadian Phosphate Limited (CP8) ORDINARY FULLY PAID |
Materials |
$24 |
Application for quotation of securities - CP8
|
27 Feb 2025 6:28PM |
n/a |
$0.070 |
n/a
|
|
| Estrella Resources Limited (ESR) ORDINARY FULLY PAID |
Materials |
$73 |
Application for quotation of securities - ESR
|
27 Feb 2025 6:27PM |
$0.027 |
$0.033 |
risen by
22.22%
|
|
| Perenti Limited (PRN) ORDINARY FULLY PAID |
Materials |
$2,284 |
Update - Notification of buy-back - PRN
|
27 Feb 2025 6:27PM |
$1.250 |
$2.430 |
risen by
94.40%
|
|
| Queste Communications Limited (QUE) ORDINARY FULLY PAID |
Financials |
$2 |
Half Year Report - 31 December 2024
|
27 Feb 2025 6:27PM |
$0.044 |
$0.056 |
risen by
27.27%
|
|
QUE - Price-sensitive ASX Announcement
Full Release
Key Points
- Total revenues increased to $110,541, a rise of 360%.
- Consolidated profit after tax increased to $1,182,752, marking an 833% rise.
- The report identifies an income tax benefit contributing to improved financial performance.
- The company continues to manage accumulated losses despite operational successes.
- Investments primarily involve Orion Equities Limited.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Cobalt Blue Holdings Limited (COB) ORDINARY FULLY PAID |
Materials |
$42 |
R&D advance loan facility and CMAI instalment receipt
|
27 Feb 2025 6:25PM |
$0.054 |
$0.072 |
risen by
33.33%
|
|
COB - Price-sensitive ASX Announcement
Full Release
Key Points
- Cobalt Blue Holdings Limited secured $700,000 loan from Radium Capital.
- Loan is secured against the R&D Tax Incentive refund for FY25.
- Funding will assist in finalizing the production flowsheet for the Kwinana Refinery Project.
- Received a CMAI grant installment of $500,000.
- Total grant funds received to date amount to $14.0 million.
- Cash and equivalents on hand total $2.94 million as of February 27, 2025.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Cambium Bio Limited (CMB) ORDINARY FULLY PAID |
Health Care |
$12 |
Half Year Report and Accounts
|
27 Feb 2025 6:25PM |
$0.400 |
$0.525 |
risen by
31.25%
|
|
CMB - Price-sensitive ASX Announcement
Full Release
Key Points
- Cambium Bio Limited reported a loss of $1.73 million for the half-year ending December 31, 2024.
- The company's revenue for the period was $278k, mainly from royalty payments.
- R&D expenses increased significantly to $1.58 million compared to $30k in the previous year.
- Cambium Bio raised $3 million in capital, strengthening its financial position.
- Elate Ocular® received FDA Fast Track designation, facilitating its journey towards Phase 3 clinical trials.
- Cash reserves at the end of the reporting period were $548k, with additional funds expected from pending approvals.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Atlas Pearls Ltd (ATP) ORDINARY FULLY PAID |
Consumer Discretionary |
$83 |
Appendix 4D and Half-Year Report
|
27 Feb 2025 6:23PM |
$0.145 |
$0.190 |
risen by
31.03%
|
|
ATP - Price-sensitive ASX Announcement
Full Release
Key Points
- Total revenue decreased by 29% to $19,133,938.
- Net profit after tax fell by 38% to $12,724,611.
- Average selling price per pearl decreased from $103 to $65.
- The company harvested 250,000 pearls during the period.
- Interim dividend of 0.61 cents per share declared.
- Special dividend of 0.39 cents per share declared.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Orion Equities Limited (OEQ) ORDINARY FULLY PAID |
Financials |
$3 |
Half Year Report - 31 December 2024
|
27 Feb 2025 6:19PM |
$0.130 |
$0.185 |
risen by
42.31%
|
|
OEQ - Price-sensitive ASX Announcement
Full Release
Key Points
- Total revenues increased to $123,584 from $33,043.
- Net loss before tax was $170,292.
- Recognized an income tax benefit of $1.41 million.
- Profit after tax amounted to $1,241,234.
- No dividends were declared for the financial half year.
- Net tangible asset backing per share reported at $0.415.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Brightstar Resources Limited (BTR) ORDINARY FULLY PAID |
Materials |
$466 |
Change of Director's Interest Notice
|
27 Feb 2025 6:13PM |
$0.020 |
$0.570 |
risen by
2,750%
|
|
| Pengana Capital Group Limited (PCG) ORDINARY FULLY PAID |
Financials |
$74 |
Shareholder Presentation Results 31 December 2024
|
27 Feb 2025 6:12PM |
$0.900 |
$0.753 |
fallen by
16.39%
|
|
PCG - Price-sensitive ASX Announcement
Full Release
Key Points
- Strong profitability in H1 FY 2025.
- Interim dividend increased to 2 cents per share, up 100% from the prior year.
- Underlying profit before tax rose to $8.173 million.
- Performance fees returned significantly following successful fund performances.
- Funds under management growth driven by higher margin products.
- Successful launch of Global Private Credit funds contributing to revenue.
- Reported earnings per share on underlying profit increased to 5.28 cps.
- Statutory profit after tax attributable to shareholders improved to $3.498 million.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Entyr Limited (ETR) ORDINARY FULLY PAID |
Industrials |
- |
Further Extension of DOCA end date
|
27 Feb 2025 6:11PM |
$0.007 |
$0.007 |
fallen by
0%
|
|
| Zoom2u Technologies Limited (Z2U) ORDINARY FULLY PAID |
Information Technology |
- |
Half Yearly Report and Accounts
|
27 Feb 2025 6:11PM |
$0.069 |
$0.051 |
fallen by
26.09%
|
|
Z2U - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue increased to $3,192,607, a 10% rise from last period.
- Loss after tax reduced by 50% to $846,058.
- Locate2u revenue grew by 10% to $1,324,489.
- Zoom2u courier platform revenue declined by 3% to $1,531,575.
- Operating costs decreased, contributing to an EBITDA of $45,027.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Australian Gold and Copper Ltd (AGC) ORDINARY FULLY PAID |
Materials |
$59 |
Change of Director's Interest Notice
|
27 Feb 2025 6:09PM |
$0.165 |
$0.220 |
risen by
33.33%
|
|
| Bio-Gene Technology Ltd (BGT) ORDINARY FULLY PAID |
Materials |
$9 |
Appendix 4D and Half-Year Accounts 31 December 2024
|
27 Feb 2025 6:09PM |
$0.033 |
$0.031 |
fallen by
6.06%
|
|
BGT - Price-sensitive ASX Announcement
Full Release
Key Points
- Loss for the half-year of $1,464,772, down from the previous year's loss.
- Collaboration with Envu to develop Flavocide for mosquito management.
- Completion of pilot-scale production of Flavocide by Rallis India.
- Thirteenth Qcide harvest completed.
- Secured two grants from the U.S. Department of Defense totaling $3 million.
- Significant strengthening of intellectual property portfolio with new patents.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Pengana Capital Group Limited (PCG) ORDINARY FULLY PAID |
Financials |
$74 |
Dividend/Distribution - PCG
|
27 Feb 2025 6:07PM |
$0.900 |
$0.753 |
fallen by
16.39%
|
|
| Pengana Capital Group Limited (PCG) ORDINARY FULLY PAID |
Financials |
$74 |
PCG Appendix 4D and Interim Report 31 December 2024
|
27 Feb 2025 6:06PM |
$0.900 |
$0.753 |
fallen by
16.39%
|
|
PCG - Price-sensitive ASX Announcement
Full Release
Key Points
- Profit for the half-year is $3,498,000, up from a loss of $873,000.
- Revenue from ordinary activities increased by 92% to $34,906,000.
- Declared an interim dividend of 2.0 cents per share.
- Total assets amounted to $127,780,000.
- Total equity reached $86,182,000.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| St Barbara Limited (SBM) ORDINARY FULLY PAID |
Materials |
$950 |
Updated Appendix 3Y Mark Hine
|
27 Feb 2025 6:04PM |
$0.230 |
$0.785 |
risen by
241.30%
|
|
| Peregrine Gold Ltd (PGD) ORDINARY FULLY PAID |
Materials |
$21 |
Appointment of Joint Company Secretary
|
27 Feb 2025 6:04PM |
$0.115 |
$0.215 |
risen by
86.96%
|
|